GGrantIndex
← Search

Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes

$1,001,699ZIAFY2017CANIH

Division Of Basic Sciences - Nci

Investigators

Brigitte Widemanncontact

Linked publications & trials

Paper 32642739Paper 32607696Paper 32601387Paper 32187457Paper 32152628Paper 31913576Paper 30908877Paper 30908866Paper 30803705Paper 30302932Paper 30302402Paper 30270358Paper 29987133Paper 29987129Paper 29718344Paper 29681099Paper 29649040Paper 29570943Paper 29409029Paper 29138631Paper 29097016Paper 28735371Paper 28328340Paper 28068329Paper 28029918Paper 27817916Paper 27527649Paper 27527645Paper 27510726Paper 27155140Paper 27021207Paper 26976425Paper 26829601Paper 26360873Paper 24753394Paper 24617713Paper 24500418Paper 24443315Paper 24321536Paper 23453281Paper 23221341Paper 23089139Paper 23035791Paper 22961690Paper 22645095Paper 22353803Paper 19841379Paper 19671848Paper 19508838Paper 18559970Paper 18071635Paper 17509460Paper 17215493

Abstract

The mission of the Pharmacology & Experimental Therapeutics Section (PETS) of NCI's Pediatric Oncology Branch (POB) is to develop more effective treatments for children and young adults with refractory cancers and genetic tumor predisposition syndromes (GTPS). A particular focus is on rare tumors with unmet need. Promising novel agents are studied in early clinical trials that evaluate toxicities, activity, pharmacokinetics, and pharmacodynamics. By leveraging unique NIH resources, I have applied the principles of drug development for refractory cancers to neurofibromatosis type 1 (NF1)-related tumors and built the nation's largest comprehensive NF1 clinical trials program directed at plexiform neurofibromas (PN) and malignant peripheral nerve sheath tumors (MPNST).

View original record on NIH RePORTER →